JP6215056B2 - 拮抗性ｄｒ３リガンド - Google Patents

拮抗性ｄｒ３リガンド Download PDF

Info

Publication number
JP6215056B2
JP6215056B2 JP2013555876A JP2013555876A JP6215056B2 JP 6215056 B2 JP6215056 B2 JP 6215056B2 JP 2013555876 A JP2013555876 A JP 2013555876A JP 2013555876 A JP2013555876 A JP 2013555876A JP 6215056 B2 JP6215056 B2 JP 6215056B2
Authority
JP
Japan
Prior art keywords
antibody
cells
seq
fab
tl1a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013555876A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014509325A (ja
JP2014509325A5 (https=
Inventor
メッテ・ダール・アンデルセン
ペダー・リスビー・ノービー
クリスティアン・ケアゴー
スザンヌ・ニーザゴー・グレル
アルブレヒト・グルーラー
イェンス・ブヒアルト
ヘンリク・スーン・アンデルセン
ソーレン・パズクイェー
イェスパー・カストロプ
カタリーナ・ホーカンソン
ラルス・ホアノム
ビアギッテ・フリードリクセン
ドーリト・バウンスゴー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2014509325A publication Critical patent/JP2014509325A/ja
Publication of JP2014509325A5 publication Critical patent/JP2014509325A5/ja
Application granted granted Critical
Publication of JP6215056B2 publication Critical patent/JP6215056B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013555876A 2011-03-01 2012-03-01 拮抗性ｄｒ３リガンド Expired - Fee Related JP6215056B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11156416.7 2011-03-01
EP11156416 2011-03-01
US201161448827P 2011-03-03 2011-03-03
US61/448,827 2011-03-03
PCT/EP2012/053539 WO2012117067A1 (en) 2011-03-01 2012-03-01 Antagonistic dr3 ligands

Publications (3)

Publication Number Publication Date
JP2014509325A JP2014509325A (ja) 2014-04-17
JP2014509325A5 JP2014509325A5 (https=) 2015-04-23
JP6215056B2 true JP6215056B2 (ja) 2017-10-18

Family

ID=44210048

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013555876A Expired - Fee Related JP6215056B2 (ja) 2011-03-01 2012-03-01 拮抗性ｄｒ３リガンド

Country Status (12)

Country Link
US (4) US9737612B2 (https=)
EP (1) EP2681237A1 (https=)
JP (1) JP6215056B2 (https=)
KR (1) KR20140043720A (https=)
CN (1) CN103517918A (https=)
BR (1) BR112013022052A2 (https=)
CA (1) CA2828464A1 (https=)
IL (1) IL227535A0 (https=)
MX (1) MX2013009859A (https=)
RU (1) RU2013141079A (https=)
WO (1) WO2012117067A1 (https=)
ZA (1) ZA201306110B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2972330A4 (en) * 2013-03-15 2016-10-26 Alder Biopharmaceuticals Inc PROTOCOL FOR THE IDENTIFICATION AND ISOLATION OF ANTIGEN-SPECIFIC B-CELLS AND FOR THE PREPARATION OF ANTIBODIES FOR DESIRED ANTIGENES
WO2015036553A1 (en) 2013-09-16 2015-03-19 Novo Nordisk Health Care Ag Thiol functionalized polymers
US9416197B2 (en) 2013-11-01 2016-08-16 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
SG11201608253XA (en) 2014-04-04 2016-10-28 Kyowa Hakko Kirin Co Ltd Anti-death receptor 3 (dr3) antagonistic antibodies with reduced agonistic activity
EP3137495A4 (en) * 2014-04-28 2017-11-15 The National Institute for Biotechnology in the Negev, Ltd. Variants of dr3 and use thereof
EP3572502B1 (en) * 2017-01-20 2023-01-11 Kyoto University Method for producing cd8alpha +beta + cytotoxic t cells
EP3860653A1 (en) 2018-10-05 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
CN111808183B (zh) * 2020-07-25 2022-07-08 北京吉尔麦迪生物医药科技有限公司 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白
US20250249278A1 (en) 2022-04-14 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
EP4501966A4 (en) * 2022-06-17 2025-10-22 Selecxine Inc ANTIBODY SPECIFICALLY BINDING TO HUMAN DR3 AND ITS USE
CN116223818B (zh) * 2023-05-09 2023-07-21 四川大学华西医院 Dr3蛋白检测试剂在制备筛查aecopd的试剂盒的用途及筛查aecopd的试剂盒
CN120399074B (zh) * 2023-06-02 2025-12-30 安徽金百奥生物科技有限公司 一种与人dr3胞外域高亲和力的纳米抗体
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
GB202315963D0 (en) 2023-10-18 2023-11-29 Cancer Research Tech Ltd Binding molecules
WO2025158389A1 (en) 2024-01-24 2025-07-31 Shattuck Labs, Inc. Antibodies that bind tnfrsf25

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
CN101070344A (zh) 1998-04-30 2007-11-14 泰诺士公司 G－csf受体兴奋剂抗体及其筛选方法
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
CA2371114A1 (en) * 1999-04-22 2000-11-02 Human Genome Sciences, Inc. Death domain containing receptors
CA2391530A1 (en) * 1999-11-19 2001-05-25 Thomas V. Tittle Tr3-specific binding agents and methods for their use
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US7148061B2 (en) 2000-02-11 2006-12-12 The United States Of America As Represented By The Department Of Health And Human Services Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
WO2002040680A2 (en) 2000-11-17 2002-05-23 The Burnham Institute Death domain proteins
US20040234524A1 (en) 2001-04-05 2004-11-25 Toshimitsu Uede Anti-osteopontin antibody and use thereof
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
KR100499989B1 (ko) 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
US20090317388A1 (en) * 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
JP5164167B2 (ja) * 2005-08-30 2013-03-13 ユニバーシティー オブ マイアミ 免疫調節性腫瘍壊死因子受容体２５（ｔｎｆｒ２５）のアゴニスト、アンタゴニスト及び免疫毒素
US20110195048A1 (en) 2008-10-08 2011-08-11 Podack Eckhard R Regulation of lymphocytes and uses therefor
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3

Also Published As

Publication number Publication date
ZA201306110B (en) 2014-04-30
EP2681237A1 (en) 2014-01-08
BR112013022052A2 (pt) 2016-11-22
CN103517918A (zh) 2014-01-15
US9737612B2 (en) 2017-08-22
US8765130B2 (en) 2014-07-01
JP2014509325A (ja) 2014-04-17
US20130330360A1 (en) 2013-12-12
RU2013141079A (ru) 2015-04-10
IL227535A0 (en) 2013-09-30
MX2013009859A (es) 2014-02-28
US20130336984A1 (en) 2013-12-19
US20170305994A1 (en) 2017-10-26
US20140294853A1 (en) 2014-10-02
WO2012117067A1 (en) 2012-09-07
CA2828464A1 (en) 2012-09-07
KR20140043720A (ko) 2014-04-10
US9713644B2 (en) 2017-07-25

Similar Documents

Publication Publication Date Title
JP6215056B2 (ja) 拮抗性ｄｒ３リガンド
AU2022201145B2 (en) FcRn antibodies and methods of use thereof
CN106459216B (zh) 多特异性抗体构建体
ES2996834T3 (en) Binding molecules with modified j-chain
CN102164962B (zh) 抗gd2抗体和方法及其相关应用
US20190153092A1 (en) Anti-ror1 antibodies
US20170158755A1 (en) Anti-laminin4 antibodies specific for lg1-3
AU2012222342A1 (en) Antagonistic DR3 ligands
HK40103769A (en) Fcrn antibodies and methods of use thereof
HK1247218B (en) Fcrn antibodies and methods of use thereof
HK1247218A1 (en) Fcrn antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160229

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160831

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170502

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170821

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170920

R150 Certificate of patent or registration of utility model

Ref document number: 6215056

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees